The Lifelong Burden of Homozygous Familial Hypercholesterolemia.

Ambuja Banerjee, Latifah Alothman, Patrick Couture, Jean Bergeron, Alexandre M Bélanger, Isabelle Ruel, Jacques Genest

Journal: The Canadian journal of cardiology 2020;35(10):1419.e1-1419.e4

PMID: 31521416

Full Text on Elsevier Science View on PubMed

Abstract

Homozygous familial hypercholesterolemia is caused by mutations in the low-density lipoprotein receptor gene. It is diagnosed in children or youth who present with extensive tendinous and cutaneous xanthomas and extreme elevation of low-density lipoprotein cholesterol. Untreated, premature coronary artery disease develops in the teenage years or earlier and survival to ages older than 30 years is rare. Herein we describe the clinical course of a patient with homozygous familial hypercholesterolemia treated according to the standards of care and experimental approaches. Despite aggressive therapies, atherosclerosis in all vascular beds progressed, leading to the patient's demise at age 59 years, highlighting the importance of early diagnosis and appropriate follow-up.

Address: Research Institute of the McGill University Health Centre, Royal Victoria Hospital, Montreal, Quebec, Canada.; Endocrinology and Nephrology Unit, CHU de Québec-Université Laval Research Center, Qué́bec City, Quebec, Canada.; Research Institute of the McGill University Health Centre, Royal Victoria Hospital, Montreal, Quebec, Canada. Electronic address: [email protected].

DOI: 10.1016/j.cjca.2019.06.009

Link outs

Subscription / membership required

Full Text Sources:

MeSH Terms: Cost of Illness, Fatal Outcome, Homozygote, Humans, Hyperlipoproteinemia Type II, Male, Middle Aged